Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 9
Summary
- Conditions
- ARDS, Human
- COVID
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: This is an open label, dose escalating safety study of the advanced therapy investigational medicinal product (ATIMP) KI-MSC-PL-205, where patients diagnosed with SARS-CoV-2-induced severe acute respiratory distress syndrome (ARDS).Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 65 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04447833
- Collaborators
- Uppsala University Hospital
- Investigators
- Principal Investigator: Oscar Simonsson, MD, PhD Uppsala University
Get Well Soon